Glioblastoma
multiforme (GBM) is the most aggressive brain tumor,
characterized by short median survival and an almost 100% tumor-related
mortality. The standard of care treatment for newly diagnosed GBM
includes surgical resection followed by concomitant radiochemotherapy.
The prevention of disease progression fails due to the poor therapeutic
effect caused by the great molecular heterogeneity of this tumor.
Previously, we exploited synchrotron radiation-based soft X-ray tomography
and hard X-ray fluorescence for elemental microimaging of the shock-frozen
GBM cells. The present study focuses instead on the biochemical profiling
of live GBM cells and provides new insight into tumor heterogenicity.
We studied bio-macromolecular changes by exploring the live-cell synchrotron-based
Fourier transform infrared (SR-FTIR) microspectroscopy in a set of
three GBM cell lines, including the patient-derived glioblastoma cell
line, before and after riluzole treatment, a medicament with potential
anticancer properties. SR-FTIR microspectroscopy shows that GBM live
cells of different origins recruit different organic compounds. The
riluzole treatment of all GBM cell lines mainly affected carbohydrate
metabolism and the DNA structure. Lipid structures and protein secondary
conformation are affected as well by the riluzole treatment: cellular
proteins assumed cross β-sheet conformation while parallel β-sheet
conformation was less represented for all GBM cells. Moreover, we
hope that a new live-cell approach for GBM simultaneous treatment
and examination can be devised to target cancer cells more specifically,
i.e., future therapies can develop more specific treatments according
to the specific bio-macromolecular signature of each tumor type.